Journal of Liver: Disease & TransplantationISSN: 2325-9612

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article, J Liver Disease Transplant Vol: 5 Issue: 2

Down-Staging Hepatocellular Carcinoma: A Survey of Clinical Practices and Attitudes

Jesse M Civan*, She-Yan Wong, Dina Halegoua-DeMarzio and Steven K Herrine
Department of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, USA
Corresponding author : Jesse M Civan
Department of Gastroenterology and Hepatology, Thomas Jefferson University, 132 South 10th Street, Suite 480 Main Building, PA 19107, Philadelphia, USA
Tel: 215-503-2146
E-mail: [email protected]
Received: May 25, 2016 Accepted: June 20, 2016 Published: June 26, 2016
Citation: Civan JM, Wong S, Halegoua-DeMarzio D, Herrine SK (2016) Down-Staging Hepatocellular Carcinoma: A Survey of Clinical Practices and Attitudes. J Liver Disease Transplant 5:2. doi:10.4172/2325-9612.1000139

Abstract

Hepatocellular carcinoma (HCC) can be cured with liver transplantation, if not exceeding Milan Criteria. “Down-staging” refers to the process of reducing HCC tumor burden, to allow transplant in a patient initially not satisfying these criteria. However, there is no consensus on how down-staging may best be achieved. We conducted an internet-based survey of medical and surgical directors of liver transplant centers nation-wide a series of questions regarding how they practice down-staging, and their attitudes towards these practices. We had a 21.5% response rate to our survey. Although most centers have some formal protocol defining candidacy for downstaging, only about half had a specific threshold in terms of number and size of tumors. The majority of centers did not use AFP levels to define candidacy for down-staging. A sizeable minority of centers did consider patients with portal vein tumor thrombus as candidates for down-staging. Variations in clinical practice of down-staging exist. In the absence of high-quality data on which to base more uniform down-staging protocols, such variation is likely inevitable. Such variation in practice may be beneficial, promoting exploration of the balance between accesses to transplant on one hand, while ensuring adequate post-transplant outcomes on the other hand.

Keywords: Tumor; Transplant; Down staging

Track Your Manuscript

Share This Page